Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 January 2022 | Story Rulanzen Martin | Photo Supplied
Dr Mpumelelo Ncube
Dr Mpumelelo Ncube is a dynamic an academic with a clear vision of growth for the Department of Social work and its students.

A drive to be an advocate for social justice is what drove Dr Mpumelelo Ncube, the new head of the Department of Social Work, to pursue a degree and career in Social Work. “I needed to be an advocate for social justice and empowerment of the vulnerable individuals and communities,” said Dr Ncube, who took over from Prof Sandra Ferreira earlier this year. 

Dr Ncube’s academic and professional repertoire is exceptional and his deep-rooted passion for social work is definitely a bonus for the UFS Department of Social Work. He has a PhD in Social Work from the University of Johannesburg, a master’s degree in Social Development, and a Bachelor’s degree in Social Work from the University of Witwatersrand. 

Driven by the need to succeed in whatever task he sets for himself, Dr Ncube says that he strives to make the lives of those in his path better – “The positive change should, however, begin with me so that others could easily believe in my efforts.” 

Opportunity to raise a new generation

He joined academia in 2013 after working as a psychosocial services manager in the NGO sector. “My move to the UFS was in line with my career progression and the need to contribute meaningfully at a strategic level of social work education and practice,” Dr Ncube says.  

The opportunity to work in academia has in fact provided him with an excellent opportunity. “I have the opportunity to raise a new generation of social work professionals that would be passionate, ethical and professional in their practice. In that way, my impact as an educator can be felt in all corners where my students are,” Dr Ncube says. 

An academic of note 

As a senior lecturer, he also notes the tidal changes currently sweeping through academia. He says, “In the age of the fourth industrial revolution, the Social Work academic programme should be able to identify and embrace various developments that would provide the flexibility to attract postgraduate students in different places without the need for relocation. This relates to the delivery of the programme. However, apart from adapting to these changes, the Social Work programme should also foster a cultural innovation with students and enable them to embrace the technological advancements in their social work practice.”

“I have the opportunity to raise a new generation of social work professionals that would be passionate, ethical and professional in their practice.” – Dr Mpumelelo Ncube. 


Apart from being an advocate for social justice and a lecturer he also sees his position as HOD as a being a catalyst to enable others within the department to publishing more research. “Research is a key performance area for any academic, hence the mantra, ‘publish or perish’,” he says. However, he also cautions that trick of publishing research lies in “self-discipline, self-motivation and finding a research niche”.  

Social work is his passion

Social work is Dr Ncube’s passion but he also says that it is a profession, which is “seriously underutilised especially in under developing nations”. The socio-economic conditions in these countries largely drive the underutilisation. “These are nations largely plagued by poverty, unemployment, political illiteracy challenges with policy development and implementation, and moral degeneration among many challenges,” he says. In addition, it is therefore, as Dr Ncube mentions, that “the relevance of the social work profession shall be ever-present”.

  

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept